Zenosense, Inc. (ZENO) Developing Handheld Diagnostic Device to Provide Rapid Cardiac Biomarker Tests

Diagnostic devices are a crucial part of the medical technology sector, and many companies are pressing forward with work in this area. Zenosense, Inc. (OTC: ZENO) has just announced breakthrough quantitative test results for its MIDS Cardiac handheld diagnostic technology, under development to provide rapid cardiac biomarker tests in emergency settings. Thermo Fisher Scientific, Inc. (NYSE: TMO) has developed devices to streamline protein characterization, improve analysis of small molecules, and improve the speed and confidence of laboratory spectrometry. Merit Medical Systems, Inc. (NASDAQ: MMSI) has recently finalized a deal with NinePoint Medical that will increase access to NinePoint’s groundbreaking platform for the detection of esophageal cancer. Abbott Laboratories (NYSE: ABT) has undertaken the U.S. launch of an analyzer to help diabetics diagnose their state of health. And Koninklijke Philips N.V. (NYSE: PHG) has acquired Remote Diagnostic Technologies to increase its offering of frontline diagnostic tools, which include invaluable devices for emergency medicine.